Terms: = Breast cancer AND PAM50 AND Prognosis
121 results:
1. BIRC5 expression by race, age and clinical factors in breast cancer patients.
Hamilton AM; Walens A; Van Alsten SC; Olsson LT; Nsonwu-Farley J; Gao X; Kirk EL; Perou CM; Carey LA; Troester MA; Abdou Y
Breast Cancer Res; 2024 Mar; 26(1):50. PubMed ID: 38515208
[TBL] [Abstract] [Full Text] [Related]
2. Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
Ren H; Wang Z; Zhang L; Zhu G; Li F; Chen B
BMC Cancer; 2024 Mar; 24(1):367. PubMed ID: 38515057
[TBL] [Abstract] [Full Text] [Related]
3. Caveolin-1 gene expression provides additional prognostic information combined with pam50 risk of recurrence (ROR) score in breast cancer.
Godina C; Belting M; Vallon-Christersson J; Isaksson K; Bosch A; Jernström H
Sci Rep; 2024 Mar; 14(1):6675. PubMed ID: 38509243
[TBL] [Abstract] [Full Text] [Related]
4. B-Cell-Mediated Immunity Predicts Survival of Patients With Estrogen Receptor-Positive breast cancer.
Lee S; Kang BH; Lee HB; Jang BS; Han W; Kim IA
JCO Precis Oncol; 2024 Mar; 8():e2300263. PubMed ID: 38452311
[TBL] [Abstract] [Full Text] [Related]
5. NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.
Mendiburu-Eliçabe M; García-Sancha N; Corchado-Cobos R; Martínez-López A; Chang H; Hua Mao J; Blanco-Gómez A; García-Casas A; Castellanos-Martín A; Salvador N; Jiménez-Navas A; Pérez-Baena MJ; Sánchez-Martín MA; Abad-Hernández MDM; Carmen SD; Claros-Ampuero J; Cruz-Hernández JJ; Rodríguez-Sánchez CA; García-Cenador MB; García-Criado FJ; Vicente RS; Castillo-Lluva S; Pérez-Losada J
Clin Transl Med; 2024 Feb; 14(2):e1554. PubMed ID: 38344872
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.
Cisneros-Villanueva M; Fonseca-Montaño MA; Ríos-Romero M; López-Camarillo C; Jiménez-Morales S; Langley E; Rosette-Rueda AS; Cedro-Tanda A; Hernández-Sotelo D; Hidalgo-Miranda A
Sci Rep; 2024 Jan; 14(1):1483. PubMed ID: 38233470
[TBL] [Abstract] [Full Text] [Related]
7. miR-877-5p as a Potential Link between Triple-Negative breast cancer Development and Metabolic Syndrome.
Moro J; Grinpelc A; Farré PL; Duca RB; Lacunza E; Graña KD; Scalise GD; Dalton GN; Massillo C; Piccioni F; Dimase F; Batagelj E; De Siervi A; De Luca P
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069080
[TBL] [Abstract] [Full Text] [Related]
8. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Rediti M; Fernandez-Martinez A; Venet D; Rothé F; Hoadley KA; Parker JS; Singh B; Campbell JD; Ballman KV; Hillman DW; Winer EP; El-Abed S; Piccart M; Di Cosimo S; Symmans WF; Krop IE; Salgado R; Loi S; Pusztai L; Perou CM; Carey LA; Sotiriou C
Nat Commun; 2023 Nov; 14(1):7053. PubMed ID: 37923752
[TBL] [Abstract] [Full Text] [Related]
9. Application Of Multigene Panel Detection In breast cancer.
Zhao Y; Xiong D; Yang B; Xia S; Zhang X
J Pak Med Assoc; 2023 Sep; 73(9):1862-1868. PubMed ID: 37817699
[TBL] [Abstract] [Full Text] [Related]
10. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER pam50 assay: a real-world study.
Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
[TBL] [Abstract] [Full Text] [Related]
11. Transcriptional intra-tumour heterogeneity predicted by deep learning in routine breast histopathology slides provides independent prognostic information.
Wang Y; Ali MA; Vallon-Christersson J; Humphreys K; Hartman J; Rantalainen M
Eur J Cancer; 2023 Sep; 191():112953. PubMed ID: 37494846
[TBL] [Abstract] [Full Text] [Related]
12. Bioinformatics analysis of the clinicopathological and prognostic significance of BAG3 mRNA in gynecological cancers.
Wang ZM; Zhang L; Ren DH; Zhang CY; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(2):2228899. PubMed ID: 37377218
[TBL] [Abstract] [Full Text] [Related]
13. A bioinformatics analysis of the clinicopathological and prognostic significance of
Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
[TBL] [Abstract] [Full Text] [Related]
14. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
[TBL] [Abstract] [Full Text] [Related]
15. Quantification of subtype purity in Luminal A breast cancer predicts clinical characteristics and survival.
Kumar N; Gann PH; McGregor SM; Sethi A
Breast Cancer Res Treat; 2023 Jul; 200(2):225-235. PubMed ID: 37209182
[TBL] [Abstract] [Full Text] [Related]
16. Reproducibility and intratumoral heterogeneity of the pam50 breast cancer assay.
Hurson AN; Hamilton AM; Olsson LT; Kirk EL; Sherman ME; Calhoun BC; Geradts J; Troester MA
Breast Cancer Res Treat; 2023 May; 199(1):147-154. PubMed ID: 36892725
[TBL] [Abstract] [Full Text] [Related]
17. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early breast cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract] [Full Text] [Related]
18. prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature.
Luo Y; Tian W; Lu X; Zhang C; Xie J; Deng X; Xie Y; Yang S; Du W; He R; Wei W
Front Immunol; 2022; 13():1056680. PubMed ID: 36524129
[TBL] [Abstract] [Full Text] [Related]
19. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
[TBL] [Abstract] [Full Text] [Related]
20. The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis.
E Y; Xue H; Zhang CY; Zhao MZ; Zheng HC
Histol Histopathol; 2023 Apr; 38(4):453-465. PubMed ID: 36255176
[TBL] [Abstract] [Full Text] [Related]
[Next]
